openPR Logo
Press release

Microbiome Diagnostics Market Size, Growth, Opportunities, Share, Key Segments, Regional Analysis, Top Companies and Forecast to 2028

06-26-2024 12:40 AM CET | Health & Medicine

Press release from: ABNewswire

The Genetic Analysis (Norway) entered into an agreement with Eagle Biosciences Inc. (US) through its distributors with an undisclosed partner. A high-volume lab company providing laboratory diagnostics to clinics, public health departments and research un

The Genetic Analysis (Norway) entered into an agreement with Eagle Biosciences Inc. (US) through its distributors with an undisclosed partner. A high-volume lab company providing laboratory diagnostics to clinics, public health departments and research un

The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
Microbiome Diagnostics Market [https://www.prnewswire.com/news-releases/microbiome-diagnostics-market-worth-300-million--marketsandmarkets-302068386.html] in terms of revenue was estimated to be worth $146 million in 2023 and is poised to reach $300 million by 2028, growing at a CAGR of 15.5% from 2023 to 2028 according to a new report by MarketsandMarkets Trademark . The microbiome diagnostics market is driven by the growing demand of personalized medicine, the collaborative efforts between the microbiome industry and academia for microbiome research and increasing incidences of diseases in the microbiome-based diagnostics market. Growth in emerging countries and increased collaboration of industry players to work on new microbiome technology are anticipated to offer lucrative growth opportunities for the microbiome diagnostics market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132581140 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132581140&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]

The kits & reagents accounted for the largest share of the microbiome diagnostics market, by product segment, in 2022.

The global microbiome diagnostics market is segmented into instruments and reagents & kits based on product. High consumption of consumables such as kits and reagents and their repeated purchases along with the increasing number of microbiome diagnostic tests performed across the globe, are the factors supporting the growth of the reagents & kits product segment.

The hospitals segment accounted for the largest share of the microbiome diagnostics market, by end user, in 2022.

By end user, microbiome diagnostics market segmented into hospitals, research & academic institutes and, pharmaceutical & biotechnology companies. Hospitals are accounted for largest in the microbiome diagnostics market. The increasing prevalences of diseases such as gastrointestinal disorder, metabolic disorder etc. will boost the market growth.

North America is the largest regional market for microbiome diagnostics market.

The global microbiome diagnostics market has been segmented into four major regions-North America, Europe, the Asia Pacific, and Rest of the World. In 2022, North America dominated the global microbiome diagnostics market in 2022. The large share of the North American market is primarily driven by the prevalence of chronic diseases, and the easy accessibility of technologically advanced instruments.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132581140 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=132581140&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]

Microbiome Diagnostics Market Dynamics:

Drivers:

* Growing prevalence of chronic diseases
* Collaborative efforts between microbiome industry and academia for microbiome research
* Growing demand for personalized medicine
* Rising awareness about importance of human microbiomes
* Rising funding and investments in microbiome research

Restraints:

* End-user budget constraints in developing countries

Opportunities:

* Increased collaboration between key players and small innovative companies to work on new microbiome technologies

Challenge:

* Adverse impact of complex regulatory policies on commercialization of microbiome

Key Market Players of Microbiome Diagnostics Industry:

The major players operating in this market are DNA Genotek (Canada), Microba Life Sciences (US), and Genetic Analysis AS (Norway)

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=132581140 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=132581140&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=microbiome-diagnostics-market-size-growth-opportunities-share-key-segments-regional-analysis-top-companies-and-forecast-to-2028]
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/microbiome-diagnostics-market-132581140.html



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Microbiome Diagnostics Market Size, Growth, Opportunities, Share, Key Segments, Regional Analysis, Top Companies and Forecast to 2028 here

News-ID: 3553663 • Views:

More Releases from ABNewswire

EGFR Non Small Cell Lung Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Bridge Biotherapeutics, Sichuan Kelun Pharma, BeBetter Med Inc
EGFR Non Small Cell Lung Cancer Pipeline 2025: FDA Updates, Therapy Innovations, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, EGFR Non Small Cell Lung Cancer pipeline constitutes 25+ key companies continuously working towards developing 30+ EGFR Non Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The EGFR Non Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical
Glioblastoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics
Glioblastoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Miles …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Glioblastoma pipeline constitutes 200+ key companies continuously working towards developing 220+ Glioblastoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Glioblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Detailed Drivers Launches LaGuardia Airport Car Service with Curbside and Meet & Greet
Detailed Drivers Launches LaGuardia Airport Car Service with Curbside and Meet & …
New York-based Detailed Drivers introduces premium black car and chauffeur service at LaGuardia Airport (LGA), featuring professional meet and greet pickup and service to all Manhattan, Brooklyn, and tri-state destinations. NEW YORK, NY - February 12, 2026 - Detailed Drivers, a worldwide luxury transportation provider headquartered in New York City, today announced the launch of dedicated car service operations at LaGuardia Airport (LGA), providing premium chauffeur-driven transportation for the 31 million
Distinguished Chiropractor Dr. Xuan Diep, D.C., Joins Prime Medical Evaluators as a Qualified Medical Evaluator
Distinguished Chiropractor Dr. Xuan Diep, D.C., Joins Prime Medical Evaluators a …
Yucaipa, CA - Prime Medical Evaluators (PME) is proud to announce the addition of Dr. Xuan Diep, D.C., an experienced chiropractor with more than two decades of clinical expertise, to its network of Qualified Medical Evaluators (QMEs) [https://primemedicalevaluators.com/]. Dr. Diep brings extensive experience in personal injury, workers' compensation, orthopedic coordination, and rehabilitation-based chiropractic care, further strengthening PME's commitment to delivering high-quality medical-legal evaluations throughout California. Education and Licensure Dr. Diep earned his

All 5 Releases


More Releases for Genetic

Respiratory Disease Genetic Testing Market Demand Analysis in Advanced Diagnosti …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Respiratory Disease Genetic Testing Market- (By Offerings (Products (Kits and Consumables), Services, Others), By Disease Type (COPD (Alpha-1-antitrypsin (AAT), Cystic Fibrosis (CF), Diffuse Lung Disease/Surfactant Dysfunction (RHD (Respiratory Distress Syndrome), PPHN (Persistent Pulmonary Hypertension of the Newborn)), Interstitial lung disease, Pulmonary Arterial Hypertension, Pulmonary Hypoplasia, Primary Ciliary Dyskinesia, Other Diseases (BPD)), By Offerings (PCR, NGS
Surge In Genetic Disorders Propels Growth Of Genetic Testing Market: Critical Dr …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Genetic Testing Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The genetic testing sector has experienced substantial expansion recently, projected to increase its valuation from $19.1 billion in the year 2024 to $20.84 billion by 2025, reflecting a compound annual growth rate of 9.1%. This
Preimplantation Genetic Testing Market Unlocking Innovations and Future Opportun …
𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧: The field of reproductive medicine has witnessed groundbreaking advancements in recent years, with preimplantation genetic testing (PGT) emerging as a pivotal innovation. This technology, designed to analyze embryos for genetic abnormalities before implantation during in vitro fertilization (IVF), has revolutionized assisted reproductive techniques, offering hope to countless couples seeking healthy pregnancies. The preimplantation genetic testing market is projected to grow from a value of US$0.68 billion in 2024 to US$1.48
Animal Genetic Market poised for growth with advancements in genetic testing by …
𝐀𝐧𝐢𝐦𝐚𝐥 𝐆𝐞𝐧𝐞𝐭𝐢𝐜 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰: Maximize Market Research is a Business Consultancy Firm that has published a detailed analysis of the Animal Genetic Market. The report includes key business insights, demand analysis, pricing analysis, and competitive landscape. The analysis in the report provides an in-depth aspect at the current status of the Animal Genetic market, with forecasts outspreading to the year 2030. 𝐒𝐞𝐜𝐮𝐫𝐞 𝐲𝐨𝐮𝐫 𝐬𝐚𝐦𝐩𝐥𝐞 𝐜𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞𝐥𝐲: https://www.maximizemarketresearch.com/request-sample/31913/ 𝐄𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧
Genetic Testing Services Market Report 2024 - Genetic Testing Services Market Tr …
"The Business Research Company recently released a comprehensive report on the Global Genetic Testing Services Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The genetic testing services
Breast Cancer Predictive Genetic Testing Market Breast Cancer Predictive Genetic …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Cancer Susceptibility Testing 1.1 Prologue to Cancer Susceptibility 1.2 Aspects of Cancer Susceptibility Testing Breast Cancer Susceptibility 2.1 Conceptual of Breast Cancer Susceptibility 2.2 Trail of the Inherited Susceptible Genes Hereditary Breast Cancer Genes 3.1 High Penetrant Genes 3.1.1 Breast Cancer Gene1 (BRCA1) 3.1.2 Breast Cancer Gene 2 (BRCA2)